ADM and hepatocellular carcinoma: These findings suggest ADM-targeted therapy combined with sorafenib may represent a novel precision therapeutic strategy for hepatocellular carcinoma, particularly for sorafenib-resistant patients with elevated ADM expression, providing innovative avenues to enhance targeted therapy efficacy.